Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL, USA.
FASEB J. 2021 May;35(5):e21439. doi: 10.1096/fj.202002622R.
Inflammatory bowel disease (IBD) remains a persistent health problem with a global burden surging over 6.8 million cases currently. Clinical pathology of IBD is complicated; however, hyperactive inflammatory and immune responses in the gut is shown to be one of the persistent causes of the disease. Human gut inflammasome, the activator of innate immune system is believed to be a primary underlying cause for the pathology and is largely associated with the progression of IBD. To manage IBD, there is a need to fully understand the role of inflammasome activation in IBD. Since inflammasome potentially play a significant role in IBD, systemic modulation of inflammasome may provide an effective therapeutic and clinical approach to control IBD symptoms. In this review, we have focused on this association between IBD and gut inflammasome, and recent advances in the research and therapeutic strategies for IBD. We have discussed inflammasomes and their components, outcomes from the experimental animals and human studies, inflammasome inhibitors, and developments in the inflammasome-targeted therapies for IBD.
炎症性肠病（IBD）仍然是一个全球性的健康问题，目前全球有超过 680 万例病例。IBD 的临床病理学较为复杂；然而，肠道中过度活跃的炎症和免疫反应被认为是疾病持续存在的原因之一。人类肠道炎症小体是先天免疫系统的激活剂，被认为是病理学的主要潜在原因，并且与 IBD 的进展密切相关。为了治疗 IBD，需要充分了解炎症小体激活在 IBD 中的作用。由于炎症小体在 IBD 中可能发挥重要作用，因此全身性调节炎症小体可能为控制 IBD 症状提供一种有效的治疗和临床方法。在这篇综述中，我们重点关注了 IBD 与肠道炎症小体之间的这种关联，以及 IBD 研究和治疗策略的最新进展。我们讨论了炎症小体及其组成部分、来自实验动物和人类研究的结果、炎症小体抑制剂以及针对 IBD 的炎症小体靶向治疗的发展。
